We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

94 hedge funds and large institutions have $1.35B invested in Arcutis Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

963% more call options, than puts

Call options by funds: $3.69M | Put options by funds: $347K

267% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 6

159% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 17

21% more funds holding

Funds holding: 78 → 94 (+16)

18% more capital invested

Capital invested by funds: $1.15B → $1.35B (+$202M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.4% less ownership

Funds ownership: 93.91% → 93.51% (-0.4%)

Holders
94
Holders Change
+16
Holders Change %
+20.51%
% of All Funds
1.65%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
22
Increased
44
Reduced
17
Closed
6
Calls
$3.69M
Puts
$347K
Net Calls
+$3.34M
Net Calls Change
+$3.34M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$40.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$34.1M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$27.4M
4
PCH
Polar Capital Holdings
United Kingdom
+$24.4M
5
Franklin Resources
Franklin Resources
California
+$20.4M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$32.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$13.6M
3
Goldman Sachs
Goldman Sachs
New York
-$6.35M
4
Millennium Management
Millennium Management
New York
-$4.53M
5
VC
Vivo Capital
California
-$3.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
51
UBS AM
Illinois
$613K +$662K +21,200 New
UBS Group
52
UBS Group
Switzerland
$591K +$638K +20,446 New
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$582K +$1.41K +45 +0.2%
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$527K – – –
CS
55
Credit Suisse
Switzerland
$482K -$248K -7,941 -32%
Deutsche Bank
56
Deutsche Bank
Germany
$480K -$3.1M -99,330 -86%
Millennium Management
57
Millennium Management
New York
$437K -$4.53M -145,001 -91%
IA
58
IndexIQ Advisors
New York
$431K +$466K +14,910 New
JP Morgan Chase
59
JP Morgan Chase
New York
$430K +$173K +5,527 +59%
CSS
60
Cubist Systematic Strategies
Connecticut
$398K +$377K +12,061 +706%
AllianceBernstein
61
AllianceBernstein
Tennessee
$396K -$65.6K -2,100 -13%
ProShare Advisors
62
ProShare Advisors
Maryland
$380K +$56.5K +1,809 +16%
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$375K +$27.7K +888 +7%
AA
64
AlphaCentric Advisors
Puerto Rico
$347K +$375K +12,000 New
DekaBank Deutsche Girozentrale
65
DekaBank Deutsche Girozentrale
Germany
$334K – – –
Commonwealth Equity Services
66
Commonwealth Equity Services
Massachusetts
$318K +$343K +10,994 New
Squarepoint
67
Squarepoint
New York
$308K -$1.2M -38,433 -78%
EAM
68
Erste Asset Management
Austria
$299K +$347K +11,100 New
VEA
69
Virtus ETF Advisers
New York
$298K +$5.78K +185 +2%
VOYA Investment Management
70
VOYA Investment Management
Georgia
$273K +$31.3K +1,003 +12%
BC
71
Birchview Capital
Vermont
$260K +$281K +9,000 New
MIM
72
MetLife Investment Management
New Jersey
$238K – – –
PPA
73
Parametric Portfolio Associates
Washington
$232K +$250K +8,010 New
MAM
74
Martingale Asset Management
Massachusetts
$209K +$225K +7,208 New
ASRS
75
Arizona State Retirement System
Arizona
$207K +$223K +7,152 New
1 2
3
4

ARQT Hedge Fund Activity: Q1 2021 in Review

94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2021, worth a combined $1.35B — up 18% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ARQT positions and 6 closed out — a net gain of 16 holders — while 44 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $40.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $32.8M sold.

  • 94 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2021, up from 78 in Q4 2020.
  • Funds reported $1.35B of Arcutis Biotherapeutics stock for Q1 2021, up 18% quarter-over-quarter.
  • 22 funds opened new Arcutis Biotherapeutics positions in Q1 2021 and 6 closed out, a net change of +16 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2021 was BlackRock, an estimated $40.8M added.
  • The largest Arcutis Biotherapeutics seller in Q1 2021 was RA Capital Management, an estimated $32.8M sold.

Based on aggregated 13F filings for Q1 2021.